 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...3637383940414243444546...100101» |
- | 5-fluorouracil / Generic mfg., letrozole / Generic mfg.
Journal: New functionalized 6-thienylpyrimidine-5-carbonitriles as antiproliferative agents against human breast cancer cells. (Pubmed Central) - Feb 16, 2022
6-Thienylpyrimidine-5-carbonitrile derivatives were synthesized and screened for their in vitro antiproliferative activities against two human breast cancer cell lines in comparison to 5-fluorouracil as a reference...Compound 2 exerted its effect through inhibition of the epidermal growth factor receptor (EGFR), while 6b showed less aromatase inhibitory activity than letrozole...In addition, caspase-9 protein activation assays, cell cycle analysis using flow cytometry, and annexin V-fluorescein isothiocyanate-propidium iodide (FITC/PI) dual staining assays were performed for the most active compounds. All the tested compounds were found to be potent pyrimidine derivatives able to initiate apoptosis in MCF-7 and MDA-MB-231 cells.
- || Kisqali (ribociclib) / Novartis
Trial completion date, Trial primary completion date: GOG-3026: Ribociclib and Letrozole Treatment in Ovarian Cancer (clinicaltrials.gov) - Feb 16, 2022
P2, N=51, Recruiting, Sponsor: Gynecologic Oncology Group
All the tested compounds were found to be potent pyrimidine derivatives able to initiate apoptosis in MCF-7 and MDA-MB-231 cells. Trial completion date: Dec 2021 --> Dec 2024 | Trial primary completion date: Dec 2021 --> Aug 2023
- | Verzenio (abemaciclib) / Eli Lilly
Trial completion date, Trial primary completion date, Combination therapy, Metastases: GOG-3039: Abemaciclib and Letrozole to Treat Endometrial Cancer (clinicaltrials.gov) - Feb 16, 2022
P2, N=50, Recruiting, Sponsor: Gynecologic Oncology Group
Trial completion date: Dec 2021 --> Dec 2024 | Trial primary completion date: Dec 2021 --> Aug 2023 Trial completion date: Jun 2023 --> Sep 2024 | Trial primary completion date: Jun 2022 --> Jun 2023
- || letrozole / Generic mfg.
Clinical, Clinical data, Journal: Predicting the clinical outcomes and benefit from letrozole after 5 years of treatment with aromatase inhibitors for early breast cancer: analysis from CCTG MA.17R. (Pubmed Central) - Feb 15, 2022
P3
A nomogram with good performance may be used to accurately predict distant recurrence risk and also benefits with extended treatment after 5 years of aromatase inhibitors. Future independent validation of the proposed nomogram is warranted.
- ||| gedatolisib (PF-05212384) / Celcuity
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: B2151009: A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer (clinicaltrials.gov) - Feb 15, 2022
P1b, N=141, Completed, Sponsor: Celcuity, Inc.
Future independent validation of the proposed nomogram is warranted. Active, not recruiting --> Completed | Trial completion date: Jun 2022 --> Jan 2022 | Trial primary completion date: Jun 2022 --> Jan 2022
- |||| New P2 trial: SMMART Adaptive Clinical Treatment (ACT) Trial (clinicaltrials.gov) - Feb 14, 2022
P2, N=131, Not yet recruiting, Sponsor: OHSU Knight Cancer Institute
- Kisqali (ribociclib) / Novartis
Circulating tumor DNA (ctDNA) dynamics in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first line with ribociclib (R) and letrozole (L) in the BioItaLEE trial () - Feb 13, 2022 - Abstract #MESABCS2022MESABCS_40;
- Kisqali (ribociclib) / Novartis
Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2- breast cancer () - Feb 13, 2022 - Abstract #MESABCS2022MESABCS_18;
- | metformin / Generic mfg., letrozole / Generic mfg.
Preclinical, Journal: Effects of Metformin on Reproductive, Endocrine, and Metabolic Characteristics of Female Offspring in a Rat Model of Letrozole-Induced Polycystic Ovarian Syndrome With Insulin Resistance. (Pubmed Central) - Feb 12, 2022
Metformin might have contributed to the improvement in obesity, hyperinsulinemia, and IR in F1 female offspring. The results of this study could be used as a theoretical basis in support of using metformin in the treatment of PCOS-IR patients.
- || letrozole / Generic mfg., anastrozole / Generic mfg.
Review, Journal: Should Skeletal Maturation Be Manipulated for Extra Height Gain? (Pubmed Central) - Feb 12, 2022
Administration of letrozole to boys with constitutional delay of growth puberty may increase AH, and rhGH plus anastrozole may increase AH in boys with growth hormone deficiency or idiopathic short stature, but the lack of data on attained AH and potential selective loss-of-follow-up in several studies precludes firm conclusions. GnRHas appear to have a good overall safety profile, while for aromatase inhibitors conflicting data have been reported.
- || letrozole / Generic mfg., Herceptin (trastuzumab) / Roche, everolimus / Generic mfg.
Clinical, P1 data, Journal: Phase I study of everolimus, letrozole, and trastuzumab in patients with hormone receptor-positive metastatic breast cancer or other solid tumors. (Pubmed Central) - Feb 11, 2022
P1
GnRHas appear to have a good overall safety profile, while for aromatase inhibitors conflicting data have been reported. Everolimus, letrozole, and trastuzumab has a favorable safety profile and elicits encouraging signals of anticancer activity in patients with heavily pretreated hormone receptor-and HER2-positive advanced cancers.
- || letrozole / Generic mfg., clomifene citrate / Generic mfg.
Clinical, Journal: Ovulation induction with clomiphene citrate or letrozole following laparoscopy in infertile women with minimal to mild endometriosis: a prospective randomised controlled trial. (Pubmed Central) - Feb 11, 2022
Further research could focus on prolonging cycles of ovulation induction or choosing alternative ovarian stimulation protocols. More RCTs are still needed to compare the efficacy of letrozole with CC in ovulation induction.
- | Ibrance (palbociclib) / Pfizer
Enrollment closed: LACOG1018: Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer (clinicaltrials.gov) - Feb 11, 2022
P2, N=43, Active, not recruiting, Sponsor: Latin American Cooperative Oncology Group
More RCTs are still needed to compare the efficacy of letrozole with CC in ovulation induction. Recruiting --> Active, not recruiting
- ||| Verzenio (abemaciclib) / Eli Lilly
Clinical, P3 data, Journal: Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. (Pubmed Central) - Feb 10, 2022
P3
Recruiting --> Active, not recruiting Consistent with findings in the overall population, abemaciclib plus NSAI was an effective initial treatment in the Japanese subpopulation, with a manageable safety profile.
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Feb 10, 2022
P2, N=30, Active, not recruiting, Sponsor: City of Hope Medical Center
Consistent with findings in the overall population, abemaciclib plus NSAI was an effective initial treatment in the Japanese subpopulation, with a manageable safety profile. Trial completion date: Dec 2022 --> Jul 2023 | Trial primary completion date: Apr 2020 --> Jul 2022
- | tagtociclib (PF-07104091) / Pfizer
Phase classification, Combination therapy: PF-07104091 as a Single Agent and in Combination Therapy (clinicaltrials.gov) - Feb 10, 2022
P1/2, N=240, Recruiting, Sponsor: Pfizer
Trial completion date: Dec 2022 --> Jul 2023 | Trial primary completion date: Apr 2020 --> Jul 2022 Phase classification: P2 --> P1/2
- |||| Eligard (leuprolide acetate) / Tolmar, Sanofi
Trial completion date, Trial primary completion date: OVELIA: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (clinicaltrials.gov) - Feb 10, 2022
P3, N=250, Recruiting, Sponsor: Tolmar Inc.
Phase classification: P2 --> P1/2 Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
- || Kisqali (ribociclib) / Novartis
Clinical, Journal: Ribociclib induced acute kidney injury: A case report. (Pubmed Central) - Feb 9, 2022
Ribociclib induced creatinine elevations are generally mild (grade 1-2) and can be managed by dose reduction or close monitoring of creatinine levels. We report the first case of grade 3 AKI that caused treatment discontinuation following administration of ribociclib.
- | letrozole / Generic mfg.
Biomarker, Journal: Letrozole Accelerates Metabolic Remodeling through Activation of Glycolysis in Cardiomyocytes: A Role beyond Hormone Regulation. (Pubmed Central) - Feb 8, 2022
Reduced lipid metabolism and increased glycolysis can lower energy supply to the heart, resulting in predisposition to heart failure. These data suggest that a letrozole-induced cardiac metabolic remodeling, i.e., a shift from β-oxidation to glycolysis, may induce cardiac structural remodeling.
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
New P2 trial: Shengjing-LCG011: Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC (clinicaltrials.gov) - Feb 7, 2022
P2, N=12, Not yet recruiting, Sponsor: Shengjing Hospital
- | letrozole / Generic mfg.
New trial: Live Birth After Letrozole-stimulated Cycles Versus Hormone Replacement Treatment Cycles for the First Frozen Embryo Transfer in Women With PCOS (clinicaltrials.gov) - Feb 7, 2022
P=N/A, N=1078, Not yet recruiting, Sponsor: Reproductive & Genetic Hospital of CITIC-Xiangya
- || Ibrance (palbociclib) / Pfizer
New P2 trial: Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies (clinicaltrials.gov) - Feb 7, 2022
P2, N=35, Not yet recruiting, Sponsor: Pfizer
- letrozole / Generic mfg.
Diagnostic Value of Hormonal Receptor Evaluation in Salivary Duct Adenocarcinoma (JW Marriott Phoenix Desert Ridge Resort and Spa - Grand Canyon 6-8) - Feb 6, 2022 - Abstract #MHNCS2022MHNCS_164;
As ER/PR detection is affordable and widely used we recommend routine evaluation of hormonal receptor to explore potential beneficial effects of hormonal receptor blocking agents. Future studies are required to confirm the results as well as to explore the benefit from hormonal blocking agents in SDC.
- | letrozole / Generic mfg.
Retrospective data, Journal: Retrospective cohort study on preparation regimens for frozen embryo transfer. (Pubmed Central) - Feb 5, 2022
These included relying on a woman's natural menstrual cycle, or using an oral medication called letrozole, or injectable medicine called follicle-stimulating hormone, or oestrogen and progesterone hormonal medications. The comparison found that using letrozole before transfer of a frozen embryo may be associated with higher rates of a live birth for some women.
- ||| letrozole / Generic mfg., tamoxifen / Generic mfg.
Clinical: In the subgroup analyis Tamoxifen seems to perform better than Letrozole. What’s you choice in clinical practice? (Twitter) - Feb 5, 2022
- | tamoxifen / Generic mfg.
Retrospective data, Journal, Real-world evidence: Lipid Changes During Endocrine Therapy in Breast Cancer Patients: The Results of a 5-Year Real-World Retrospective Analysis. (Pubmed Central) - Feb 4, 2022
For premenopausal BC patients, LDL levels rapidly decreased at 1 year in the tamoxifen (TAM) group compared with baseline levels (p<0.05), and this decline remained for the following 4 years...For postmenopausal BC patients, there was no significant difference in the lipid profiles (TG, TC, LDL and HDL) in the letrozole (LET), anastrozole (ANA) or exemestane (EXE) groups compared with the nonendocrine group...TAM may improve LDL and TC levels in premenopausal BC patients. In postmenopausal BC patients, aromatase inhibitors (AIs) may have no adverse effects on lipid profiles, and TAM may have limited beneficial effects on serum lipids.
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Trial completion date, Trial primary completion date: Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (clinicaltrials.gov) - Feb 4, 2022
P3, N=10000, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
In postmenopausal BC patients, aromatase inhibitors (AIs) may have no adverse effects on lipid profiles, and TAM may have limited beneficial effects on serum lipids. Trial completion date: Feb 2022 --> Feb 2023 | Trial primary completion date: Feb 2022 --> Feb 2023
- || letrozole / Generic mfg., tamoxifen / Generic mfg.
Clinical, Journal: Concomitant tamoxifen or letrozole for optimal oocyte yield during fertility preservation for breast cancer: the TAmoxifen or Letrozole in Estrogen Sensitive tumors (TALES) randomized clinical trial. (Pubmed Central) - Feb 3, 2022
P3
Tamoxifen-gonadotropin and letrozole-gonadotropin produced a similar number of mature oocytes. Women who received either tamoxifen-gonadotropin or letrozole-gonadotropin had a similar number of oocytes to the gonadotropin-only group.
- || zoledronic acid / Generic mfg.
Clinical, Journal: Gastric metastasis before diagnosis of primary invasive lobular breast carcinoma: a rare case presentation from Pakistan. (Pubmed Central) - Feb 3, 2022
The patient was treated with letrozole and zoledronic acid as first-line therapy for one year...The patient was treated with endocrine therapy containing ribociclib and treatment was ineffective confirmed by PET-CT scan...We present rare case of initial presentation of gastric metastasis before diagnosis of a primary invasive lobular breast carcinoma. Correct diagnosis and appropriate treatment were accomplished through initial clinical suspicion, accurate histological examination, and endoscopy together with analysis of disease-specific biomarkers.
- | letrozole / Generic mfg.
Preclinical, Journal: Cysteine-Cysteine Motif Chemokine Receptor 5 Expression in Letrozole-Induced Polycystic Ovary Syndrome Mice. (Pubmed Central) - Feb 3, 2022
CCR5 and CCL5 were also significantly correlated with the homeostasis model assessment of insulin resistance (HOMA-IR). Finally, the mechanisms of insulin resistance in PCOS may be caused by an increase in serine phosphorylation and a decrease in Akt phosphorylation.
- | letrozole / Generic mfg.
New P4 trial: Randomized Placebo-Controlled Clinical Trials on the Effect of Letrozole on Recovery from Non-Prescribed Androgen Use (EUDRACT) - Feb 3, 2022
P4, N=45, Not yet recruiting, Sponsor: NHMRC
- || Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Clinical, Journal: A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer. (Pubmed Central) - Feb 2, 2022
A positive correlation was observed between DBS and plasma concentrations for the 3 drugs, Lin's concordance correlation coefficients obtained by DBS normalization applying a selected strategy were 0.958 for PALBO, 0.957 for RIBO, and 0.963 for LETRO. In conclusion, a fast, easy, and reproducible DBS LC-MS/MS method for the simultaneous quantification of palbociclib; ribociclib and letrozole was developed to be used in clinical practice.
- | minocycline / Generic mfg.
Preclinical, Journal, IO biomarker: Protective Effect of Minocycline on Bax and Bcl-2 Gene Expression, Histological Damages and Oxidative Stress Induced by Ovarian Torsion in Adult Rats. (Pubmed Central) - Feb 2, 2022
Expression level of Bcl-2 was significantly increased in treated groups (P=0.001). Minocycline can repair oxidative damage in ovarian tissue and regulate apoptotic-related gene expressions.
- || letrozole / Generic mfg., cisplatin / Generic mfg., paclitaxel / Generic mfg.
Clinical, Journal: GnRHa as a treatment for letrozole-resistant recurrent adult granulosa cell tumors: A case report. (Pubmed Central) - Feb 1, 2022
Minocycline can repair oxidative damage in ovarian tissue and regulate apoptotic-related gene expressions. Hormone therapy may be an alternative to treat recurrent granulosa cell tumors, and gonadotropin-releasing hormone agonists may be a rescue treatment for aromatase inhibitor-resistant cases.
- | bicalutamide / Generic mfg.
Journal, Cancer stem cells: The HeyL-Aromatase Axis Promotes Cancer Stem Cell Properties by Endogenous Estrogen-Induced Autophagy in Castration-Resistant Prostate Cancer. (Pubmed Central) - Feb 1, 2022
The activated HeyL-aromatase axis promoted PCSC autophagy via ERα-mediated estrogenic effects. Taken together, our results indicated that the HeyL-aromatase axis could increase endogenous estradiol levels and activate ERα to suppress PCSC apoptosis by promoting autophagy, which enhances the understanding of how endogenous estrogenic effects influence CRPC development.
- || letrozole / Generic mfg.
Ugh letrozole… hated that stuff. I mean not that any part of fertility treatment is fun, but letrozole was the second worst of all the crap. The worst (for me) was the estrogen leading up to the embryo transfer. Took those 3x/day and cried 90 minutes after. Every time. (Twitter) - Jan 29, 2022
- | letrozole / Generic mfg.
Journal: Serum testosterone and oestradiol predict the growth response during puberty promoting treatment. (Pubmed Central) - Jan 28, 2022
P2/3
A threshold level of oestrogen appears to be needed for an optimal growth rate that corresponds to normal male peak height velocity of puberty. Serum testosterone 1 week after the injection and serum testosterone and oestradiol 3 months after the onset of aromatase inhibitor treatment can be used as biomarkers for treatment response in terms of growth.
- letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Computational drug design of aromatase inhibitors as a treatment for endometriosis (In-Person Room (Virtual Room)) - Jan 28, 2022 - Abstract #ACSSp2022ACS_Sp_3107;
Various computational chemistry programs, such as AMBER’s molecular dynamics (MD) and MMPBSA, were then used to assess the binding of each ligand to aromatase. Many of these ligands have shown promise as potential aromatase inhibitor drugs for the treatment of endometriosis.Figure 1: Isoflavanone scaffold
- | letrozole / Generic mfg.
Preclinical, Journal: Coupling of GPR30 mediated neurogenesis and protection with astroglial Aromatase-STAT3 signaling in rat hippocampus after global cerebral ischemia. (Pubmed Central) - Jan 27, 2022
Letrozole abolished all of the observed benefits of G1. Our results suggest that GPR30 activation mediates long-term neuroprotection and neurogenesis in the hippocampus following GCI, with potential mechanism coupling with the activation of astroglial aromatase-STAT3 signaling.
- | letrozole / Generic mfg., cyclophosphamide / Generic mfg.
Journal: Co-Delivery of Letrozole and Cyclophosphamide via Folic Acid-Decorated Nanoniosomes for Breast Cancer Therapy: Synergic Effect, Augmentation of Cytotoxicity, and Apoptosis Gene Expression. (Pubmed Central) - Jan 26, 2022
Additionally, downregulation of cyclin-D, cyclin-E, MMP-2, and MMP-9 and upregulating the expression of caspase-3 and caspase-9 genes were observed more prominently in the nanoformulation (particularly for NLCPFA) compared to the free drug. This exciting data indicated that niosome-based nanocarriers containing letrozole and cyclophosphamide with controlled release could be a promising platform for drug delivery with potential in breast cancer therapy.
- Verzenio (abemaciclib) / Eli Lilly
Phase 2, two-stage study of letrozole and abemaciclib in estrogen receptor (ER) positive recurrent or persistent endometrial cancer (Phoenix Convention Center-WB 301 ABC) - Jan 26, 2022 - Abstract #SGO2022SGO_686;
- | carotuximab IV (ENV-105) / Kairos Pharma
Trial completion date, Trial primary completion date, Metastases: Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer (clinicaltrials.gov) - Jan 26, 2022
P1/2, N=14, Active, not recruiting, Sponsor: University of Alabama at Birmingham
This exciting data indicated that niosome-based nanocarriers containing letrozole and cyclophosphamide with controlled release could be a promising platform for drug delivery with potential in breast cancer therapy. Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- |||||||||| Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
New P3 trial, Metastases: HARMONIA: Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype (clinicaltrials.gov) - Jan 25, 2022
P3, N=456, Not yet recruiting, Sponsor: SOLTI Breast Cancer Research Group
- | letrozole / Generic mfg.
New P2 trial: Letrozole and Misoprostol for Termination of Pregnancy up to 63 Days' Gestation (clinicaltrials.gov) - Jan 25, 2022
P2, N=40, Recruiting, Sponsor: Gynuity Health Projects
- ||| Tecentriq (atezolizumab) / Roche
Enrollment change, IO biomarker, MSi-H Companion diagnostic, PARP Companion diagnostic, PD(L)-1 companion diagnostic: AFT-50 EndoMAP: A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer (clinicaltrials.gov) - Jan 25, 2022
P1/2, N=100, Recruiting, Sponsor: Alliance Foundation Trials, LLC.
Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 N=60 --> 100
- | letrozole / Generic mfg.
New P4 trial: A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial (clinicaltrials.gov) - Jan 25, 2022
P4, N=60, Recruiting, Sponsor: Rigshospitalet, Denmark
- | letrozole / Generic mfg.
New P4 trial: Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation (clinicaltrials.gov) - Jan 25, 2022
P4, N=184, Recruiting, Sponsor: Rachel Mejia
- | letrozole / Generic mfg.
Trial completion: HEPAROB: Influence of Aromatase Inhibition on Hepatic- and Cardiac Function in Severe Obese Men (clinicaltrials.gov) - Jan 24, 2022
P4, N=30, Completed, Sponsor: University Hospital, Ghent
N=60 --> 100 Recruiting --> Completed
- | letrozole / Generic mfg.
New P2/3 trial: Letrozole as a Prophylaxis From GTN for Complete Mole Patients (clinicaltrials.gov) - Jan 24, 2022
P2/3, N=200, Active, not recruiting, Sponsor: Zagazig University
- || letrozole / Generic mfg., dydrogesterone / Generic mfg.
Retrospective data, Review, Journal: The Effect of Letrozole Combined with Dydrogesterone for Endometriosis in China: A Meta-Analysis. (Pubmed Central) - Jan 21, 2022
However, there was no significant difference between FSH and LH levels in both groups (p > 0.05). This combination therapy can effectively decrease the levels of VEGF, CA125, E2, P, IL-6, and TNF-a and increase the total effectiveness when comparing with the control group.